Hims and Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug ...

Novo Nordisk said on Tuesday it was partnering with telehealth firms Hims & Hers, Ro and LifeMD to sell branded versions of ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Novo Nordisk collaborates with telehealth companies to expand sales and access to its weight-loss drug Wegovy, amidst efforts ...

Brief co-hosts Brad Smith and Madison Mills examine today's trending tickers. Hims & Hers (HIMS) partners with Novo Nordisk ...

TD Cowen downgraded Hims & Hers Health to "Hold" from "Buy" citing a lack of near-term catalysts and concerns over the company’s weight loss revenue guidance in a post-compounded GLP-1 ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Hims & Hers Health (HIMS) is up more than +22% after Novo Nordisk partnered with it to offer its weight loss drug Wegovy at a reduced price through the NovoCare direct-to-consumer pharmacy platform.

Wall Street steadies as GM, Honeywell earnings clash with tariff fears. Tech stocks face pressure ahead of key reports.

Novo Nordisk announced Tuesday it will partner with telehealth providers Hims & Hers Health, Ro, and LifeMD to sell its blockbuster weight-loss drug Wegovy, aiming to widen access now that supply ...